Lorenzo Bonacchi

Lorenzo Bonacchi

Auto-generated profile, based on publicly available information

Lorenzo Bonacchi

University of Florence

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
Livio TarchiLivio Tarchi
Livio Tarchi
LBLorenzo Bonacchi
Lorenzo Bonacchi
ASAndrea Di Santo
Andrea Di Santo
PRPaolo Rovero
Paolo Rovero
CSChiara Sassoli
Chiara Sassoli
GCGiovanni Castellini
Giovanni Castellini
Introduction: Calcium/calmodulin‐dependent protein kinase kinase 1 (CAMKK1) regulates energy homeostasis through AMP‐activated protein kinase (AMPK). CAMKK1 has been implicated in appetite and satiety regulation; however, its role in obesity or type 2 diabetes mellitus (T2DM) remains unexplored. In this cross‐sectional study, the primary aim was to confirm whether CAMKK1 is elevated in individuals with diabetes. The secondary aim was to investigate CAMKK1's molecular correlates. Methods: CAMKK1 serum levels in individuals with obesity ( n = 3,061), patients with T2DM ( n = 4,910) and controls ( n = 44,257) were retrieved and compared (age, body mass index—BMI and sex‐adjusted ANCOVA). Pearson correlation coefficients and linear regression coefficients (age and BMI‐adjusted) were computed. The moderation effect of diagnostic groups was also assessed. The interaction between factors was explored by mixed graphical models. Results: CAMKK1 was elevated in patients with T2DM, in comparison to both individuals with obesity and controls (post hoc comparison, Tukey‐adjusted p = 0.010 and p = 0.044, respectively). Across diagnostic groups, positive associations were observed between CAMKK1 and AMPK (min β > 0.400, max p < 0.001) or TNFα (min > β 0.070, max p < 0.001). A positive association with leptin ( β = 0.010, p = 0.002) and ghrelin ( β = 0.005, p = 0.048) was observed only within controls. Multivariate multivariable models confirmed that specific interactions between factors were disrupted in patients with T2DM ( p < 0.001). Conclusion: These findings provide new insights into the role of CAMKK1 in obesity and T2DM. Future research may further explore CAMKK1's interplay with inflammatory pathways.

24 May 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
CDCristiano Dani
Cristiano Dani
Livio TarchiLivio Tarchi
Livio Tarchi
LBLorenzo Bonacchi
Lorenzo Bonacchi
SHSara Haydar
Sara Haydar
Emanuele CassioliEmanuele Cassioli
Emanuele Cassioli
GCGiovanni Castellini
Giovanni Castellini
Context: Anorexia nervosa (AN) is associated with severe metabolic and endocrine alterations, including growth hormone (GH) resistance and reduced insulin-like growth factor 1 (IGF-1). The longitudinal behavior of IGF-1 during treatment remains incompletely characterized. Objective: To evaluate IGF-1 levels in current and weight-restored AN, determine metabolic correlates, and examine longitudinal changes during clinical treatment. Design: Cross-sectional analysis in a population-based cohort and longitudinal analysis in a clinical cohort. Setting: UK Biobank (UKB) and a specialist eating disorder clinic. Participants: (1) UKB: 129 adult women with current AN, 2380 weight-restored AN, and 2380 healthy controls (HC) matched for age, sex, and body mass index (BMI). (2) Clinical cohort: 189 adult women with AN assessed at baseline and 12-month follow-up. Main outcome measures: Plasma IGF-1 levels; secondary metabolic and reproductive hormones, including GH, insulin, glucose, free triiodothyronine (FT3), and gonadal hormones. Results: Across the UKB groups, IGF-1 levels showed a graded pattern: lowest in current AN, medium in weight-restored AN, and highest in HC. In the clinical cohort, IGF-1 correlated positively with insulin, glucose, and FT3, and negatively with GH, consistent with GH resistance. IGF-1 levels increased significantly over 12 months of treatment (P = .003), with higher BMI at baseline predicting greater increases. Higher IGF-1 levels were associated with a greater likelihood of menstrual function independent of BMI (P < .001). Conclusion: IGF-1 appears reduced in current AN and may only partly normalize with weight restoration. IGF-1 may reflect metabolic state and reproductive function, suggesting value as an indicator of severity and treatment response.

17 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MMMatilde Marini
Matilde Marini
APAlice Papini
Alice Papini
MCMartina Chieca
Martina Chieca
EBElisa Bellantoni
Elisa Bellantoni
GPGiovanna P Pivotto
Giovanna P Pivotto
RNRomina Nassini
Romina Nassini
Nerve growth factor (NGF) is a key mediator of pain through activation of the high-affinity tropomyosin receptor kinase A (TrkA) and the low-affinity neurotrophin receptor (p75NTR). Although neuronal TrkA signaling is well established, the contribution of non-neuronal cells to NGF-dependent pain remains unclear. Here, we show that NGF and its precursor proNGF engage distinct cellular mechanisms. Intraplantar NGF induced acute nociception, heat hyperalgesia, mechanical allodynia, and cold hypersensitivity, whereas cleavage-resistant proNGF selectively evoked mechanical allodynia and cold hypersensitivity. Pharmacological and cell-specific genetic approaches demonstrated that acute nociception and heat hyperalgesia require neuronal TrkA, whereas mechanical and cold hypersensitivity depend on p75NTR activation in Schwann cells. In Schwann cells, NGF and proNGF induced p75NTR-dependent calcium release, followed by TRPA1 activation, mitochondrial ROS production, and NOX1-dependent oxidative amplification. Inhibition of ROS or TRPA1, or Schwann cell-specific Trpa1 deletion, markedly reduced mechanical allodynia and cold hypersensitivity without affecting acute nociception or heat hyperalgesia. These findings identify a Schwann cell p75NTR-ROS-TRPA1 pathway sustaining persistent pain and highlight non-neuronal p75NTR signaling as a potential therapeutic target.

16 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MMMatilde Marini
Matilde Marini
APAlice Papini
Alice Papini
MCMartina Chieca
Martina Chieca
EBElisa Bellantoni
Elisa Bellantoni
GPGiovanna Pivotto
Giovanna Pivotto
RNRomina Nassini
Romina Nassini
Nerve growth factor (NGF) is a key mediator of pain through activation of the high-affinity tropomyosin receptor kinase A (TrkA) and the low-affinity neurotrophin receptor (p75NTR). Although neuronal TrkA signaling is well established, the contribution of non-neuronal cells to NGF-dependent pain remains unclear. Here, we show that NGF and its precursor proNGF engage distinct cellular mechanisms. Intraplantar NGF induced acute nociception, heat hyperalgesia, mechanical allodynia, and cold hypersensitivity, whereas cleavage-resistant proNGF selectively evoked mechanical allodynia and cold hypersensitivity. Pharmacological and cell-specific genetic approaches demonstrated that acute nociception and heat hyperalgesia require neuronal TrkA, whereas mechanical and cold hypersensitivity depend on p75NTR activation in Schwann cells. In Schwann cells, NGF and proNGF induced p75NTR-dependent calcium release, followed by TRPA1 activation, mitochondrial ROS production, and NOX1-dependent oxidative amplification. Inhibition of ROS or TRPA1, or Schwann cell-specific Trpa1 deletion, markedly reduced mechanical allodynia and cold hypersensitivity without affecting acute nociception or heat hyperalgesia. These findings identify a Schwann cell p75NTR-ROS-TRPA1 pathway sustaining persistent pain and highlight non-neuronal p75NTR signaling as a potential therapeutic target.

30 January 2026 in Clinical and Translational Discovery
Verified
Journal Article
Open access
Livio TarchiLivio Tarchi
Livio Tarchi
AGAnnalisa Di Giacomo
Annalisa Di Giacomo
LBLorenzo Bonacchi
Lorenzo Bonacchi
ASAndrea Di Santo
Andrea Di Santo
PRPaolo Rovero
Paolo Rovero
GCGiovanni Castellini
Giovanni Castellini
Background: Diabetes, metabolic disorders and feeding behaviours continue to pose significant public health challenges. Calcium/calmodulin‐dependent protein kinase ID (CAMK1D) has recently emerged as a pivotal molecule potentially bridging peripheral metabolic control with central appetite regulation. Therefore, a comprehensive review was performed to critically evaluate and synthesize current evidence regarding the role of CAMK1D in diabetes, metabolic processes and feeding behaviours. Main text: The review assessed both published results (263 non‐duplicate studies; across Pubmed, WebOfScience and EMBASE) and the grey literature (including 14 patents, 3 clinical trials). Results from 43 unique studies, 2 patents and 5 genome‐wide association studies were finally summarized. CAMK1D modulates both metabolic processes and feeding behaviours, exhibiting tissue‐specific dynamics and diverging regulatory control either in the central nervous system (i.e., hypothalamic nuclei regulating appetite and satiety) or in the periphery (i.e., pancreatic beta cells). Genetic studies highlighted significant associations between CAMK1D polymorphisms and increased susceptibility to diabetes, obesity and altered feeding behaviours. Conclusions: CAMK1D represents an emerging molecular target with promising implications for the treatment of a wide range of clinical conditions. However, further large‐scale, mechanistic and longitudinal studies are warranted to validate its role across physiological and pathophysiological conditions, as well as to explore its future therapeutic potential.